Epidermal growth factor inhibition in solid tumours
作者： Apar Kishor Ganti , Anil Potti
DOI: 10.1517/14712598.5.9.1165
关键词:
摘要: The epidermal growth factor receptor (EGFR) plays an important role in the carcinogenesis of many human malignancies and is therefore attractive target against which anticancer therapy may be effective. At present, there are two ways this achieved clinically: antibodies EGFR inhibitors tyrosine kinase. This review describes presently approved agents cetuximab (monoclonal antibody), gefitinib erlotinib (EGFR kinase inhibitors) detail. Efficacy data for these various presented. Various other that early stages development at present have also been mentioned.
informahealthcare.com参考文章(96)
E. E. W. Cohen, D. J. Haraf, K. M. Stenson, E. Blair, B. E. Brockstein, A. M. Mauer, A. Dekker, R. Williams, E. Lester, E. E. Vokes, Integration of gefitinib (G), into a concurrent chemoradiation (CRT) regimen followed by G adjuvant therapy in patients with locally advanced head and neck cancer (HNC) - a Phase II Trial Journal of Clinical Oncology. ,vol. 23, pp. 5506- 5506 ,(2005) , 10.1200/JCO.2005.23.16_SUPPL.5506
Robert J. Motzer, Robert Amato, Mary Todd, Wen‐J Poo Hwu, Roger Cohen, Jose Baselga, Hyman Muss, Michael Cooper, Richard Yu, Michelle S. Ginsberg, Michael Needle, Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Investigational New Drugs. ,vol. 21, pp. 99- 101 ,(2003) , 10.1023/A:1022928612511
G. H. Sato, J. Mendelsohn, J. Polikoff, J. D. Sato, A. D. Le, T. Kawamoto, Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Molecular biology & medicine. ,vol. 1, pp. 511- 529 ,(1983)
Jim R Woodburn, Susan E Ashton, Simon P Guy, Keith H Gibson, Brenda J Curry, Andrew J Barker, Alan E Wakeling, ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Research. ,vol. 62, pp. 5749- 5754 ,(2002)
X.-D. Yang, A. Jakobovits, Ping Wang, C. G. Davis, X.-C. Jia, J. R. F. Corvalan, Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Research. ,vol. 59, pp. 1236- 1243 ,(1999)
Viktor Grünwald, Manuel Hidalgo, Development of The Epidermal Growth Factor Receptor Inhibitor Tarcevatm(Osi-774) Advances in Experimental Medicine and Biology. ,vol. 532, pp. 235- 246 ,(2003) , 10.1007/978-1-4615-0081-0_19
Brian Fendly, Mien Chie Hung, Robert S. Kerbel, Alicia M. Viloria Petit, Patricia Rockwell, Neil Goldstein, Janusz Rak, Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. American Journal of Pathology. ,vol. 151, pp. 1523- 1530 ,(1997)
W.K. (Bill) Evans, Gefitinib does not improve survival when combined with paclitaxel and carboplatin chemotherapy in people with advanced non-small-cell lung cancer Cancer Treatment Reviews. ,vol. 30, pp. 655- 659 ,(2004) , 10.1016/J.CTRV.2004.08.002
John K. Smith, Naila M. Mamoon, Roy J. Duhé, Emerging roles of targeted small molecule protein-tyrosine kinase inhibitors in cancer therapy. Oncology Research. ,vol. 14, pp. 175- 225 ,(2003) , 10.3727/000000003772462298
J. Baselga, D. Pfister, M.R. Cooper, R. Cohen, B. Burtness, M. Bos, G. D’Andrea, A. Seidman, L. Norton, K. Gunnett, J. Falcey, V. Anderson, H. Waksal, J. Mendelsohn, Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin Journal of Clinical Oncology. ,vol. 18, pp. 904- 914 ,(2000) , 10.1200/JCO.2000.18.4.904